Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.35 |
| ▸ | TP53 | P04637 | 8/20 | 0.34 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997045 | 0.92 | MAPT (0.40) | MAPTTP53THRBLMNASERPINE1 | |
| SCHEMBL2990698 | 0.88 | S1PR1 (0.35) | — | |
| SCHEMBL16311007 | 0.86 | KDM4E (0.34) | ALDH1A1HPGD | |
| SCHEMBL2987938 | 0.86 | KDM4E (0.34) | ALDH1A1HPGD | |
| SCHEMBL17685132 | 0.85 | MAPT (0.35) | MAPTTP53THRBLMNA | |
| SCHEMBL2996991 | 0.84 | MAPT (0.46) | MAPTTP53THRBLMNASERPINE1 | |
| SCHEMBL2999476 | 0.82 | MAPT (0.42) | MAPTTP53THRBLMNASERPINE1 | |
| SCHEMBL20490830 | 0.80 | MAPT (0.51) | MAPTTP53THRBLMNAGAA | |
| SCHEMBL3087582 | 0.80 | S1PR1 (0.35) | MAPTTP53 | |
| SCHEMBL2984877 | 0.80 | MAPT (0.34) | MAPTTP53THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970118-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2018-09-12 | — | — | EP | claimed |
| EP-2813498-B1 | Compounds for Alzheimer's disease | MANFREDI JOHN (US) | 2016-04-20 | — | — | EP | claimed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | claimed |
| EP-2813498-A1 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2014-12-17 | — | — | EP | claimed |
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2013-10-03 | — | — | US | claimed |
| CN-101068781-B | Compounds for alzheimer's disease | MYRIAD GENETICS, INC. (US) | 2012-02-01 | — | — | CN | claimed |
| EP-2970118-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2813498-B1 | Compounds for Alzheimer's disease | MANFREDI JOHN (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2813498-B1 | Compounds for Alzheimer's disease | MANFREDI JOHN (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | SLC18A2, SLC18A3, NLN | MAPT 10/4885TP53 2751/4885THRB 2651/4885 |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | MAPT 657/4885TP53 3208/4885THRB 2658/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | MAPT 46/4885TP53 306/4885THRB 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.